H. Lundbeck A/S is a Denmark-based global pharmaceutical company specializing in the research, development and commercialization of treatments for psychiatric and neurological disorders. With a focus on central nervous system (CNS) conditions, Lundbeck’s product portfolio includes antidepressants, antipsychotics, Alzheimer’s disease therapies and treatments for epilepsy, migraine and Parkinson’s disease. The company emphasizes both established small-molecule drugs and innovative approaches to meet unmet medical needs in brain health.
Among Lundbeck’s key marketed products are escitalopram (sold under the brand name Cipralex or Lexapro in various markets), the atypical antipsychotic Abilify Maintena, and vortioxetine (Trintellix/Brintellix), an antidepressant with multimodal activity. In addition to its on-market therapies, the company maintains a robust R&D pipeline with clinical-stage candidates targeting neurodegenerative diseases, mood disorders and rare neurological conditions. Lundbeck collaborates with academic institutions, biotech partners and other pharmaceutical companies to advance its early-stage discovery programs.
Founded in 1915 by Hans Lundbeck, the company has grown from a family-owned enterprise into a multinational organization with headquarters in Copenhagen, Denmark. It conducts research and manufacturing operations in Europe, North America and Asia, and markets its products in more than 50 countries worldwide. Lundbeck’s global footprint is supported by regional affiliates and partnerships that help ensure access to its CNS therapies for patients and healthcare providers across key markets.
Lundbeck’s corporate strategy centers on deepening its expertise in neuroscience, strengthening its commercial capabilities and pursuing acquisitions and alliances that complement its core CNS focus. By combining scientific innovation with a patient-centric approach, the company aims to deliver sustainable growth while addressing the complex challenges of brain health on a global scale.
AI Generated. May Contain Errors.
Free HLUYY Stock Alerts